Roche, BrunoBauhofer, ArturGomez Bravo, Miguel ÃngelPageaux, Georges PhilippeZoulim, FabienOtero, AlejandraPrieto, MartinBaliellas, CarmenSamuel, Didier2023-05-032023-05-032022-05-10http://hdl.handle.net/10668/21680BACKGROUND Self-administered subcutaneous hepatitis B immunoglobulin (s.c. HBIg) in combination with nucleos(t)ide analogs (NUCs) has proved to be effective and safe in preventing hepatitis B virus (HBV) reinfection after liver transplantation. MATERIAL AND METHODS This non-interventional, prospective, single-arm, multicenter, international study collected data on long-term effectiveness, safety, patient satisfaction (Treatment Satisfaction Questionnaire for Medication, TSQM-11), and quality of life (EQ-5D questionnaire) in routine practice over a 2-year treatment period. Data analysis was based on 195 adults (82.1% male) transplanted for HBV-related liver diseases and treated with s.c. HBIg with/without NUC(s). RESULTS HBV recurrence (seropositivity of HBV surface antigen and/or HBV DNA) was observed in 7/195 (3.6%) patients (annual rate: 2.01%). Hepatocellular carcinoma (HCC) recurred in 4/83 (4.8%) patients transplanted for HBV-HCC (annual rate: 2.88%). Twenty-nine adverse drug reactions occurred in 16/195 (8.2%) patients. Convenience and overall satisfaction scores of the TSQM-11 were significantly (PenAdultAntiviral AgentsCarcinoma, HepatocellularFemaleHepatitis BHumansImmunoglobulinsLiver NeoplasmsLiver TransplantationMaleNeoplasm Recurrence, LocalPatient Reported Outcome MeasuresProspective StudiesQuality of LifeRecurrenceReinfectionTreatment Outcomeresearch article35534995open access10.12659/AOT.9361622329-0358PMC9107284https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107284https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107284/pdf